Health & TechThe FDA approved an immunotherapy for some rectal cancer patients
Jemperli, or dostarlimab, received accelerated approval for untreated stage II or III dMMR or MSI-H rectal cancer. In a 154-patient trial, nearly three-fourths needed no chemo, radiation, or surgery after more than two years. That subtype is about 3 percent of rectal cancers.
Verified · U.S. Food and Drug Administration






